指南与共识淋巴瘤

2024年淋巴瘤研究基金会工作组关于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤治疗选择与序贯的共识推荐

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.
指南 / 共识 · Blood Adv · 2025-01-01

过去十年慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)的治疗已从传统化学免疫治疗转向靶向治疗,多种新药可及但缺乏随机试验数据指导最优选择,且美国实际诊疗中仍有患者接受化学免疫治疗。淋巴瘤研究基金会召集美国CLL/SLL专家小组制定共识推荐,作为实用临床指南补充现有指南。

要点

  • CLL/SLL治疗已从化学免疫治疗转向靶向治疗。
  • 多种新疗法可及,但缺乏随机临床试验数据指导个体化选择。
  • 美国仍有患者接受化学免疫治疗,提示指南与实践存在差距。

核心结论

  • 专家组形成CLL/SLL治疗选择与序贯的共识推荐,作为实用临床指南供治疗医生使用,并补充现有指南。

研究设计与样本

  • 淋巴瘤研究基金会召集美国CLL/SLL专家小组召开工作组会议制定共识推荐。

主要发现

  • 过去十年CLL/SLL治疗推荐已从传统化学免疫治疗转向靶向治疗。
  • 多种新疗法已商业可及,但许多情况下缺乏随机临床试验数据,使每位患者的最优治疗选择具有挑战性。
  • 美国许多患者仍在接受化学免疫治疗,提示指南与实际实践之间存在差距。

临床怎么用

  • 推荐汇编为实用临床指南,供治疗CLL/SLL患者的医生使用。
  • 推荐补充现有指南,讨论美国CLL/SLL专家小组在真实世界环境中如何照护患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and, in many cases, a lack of randomized clinical trial data makes selection of the optimal treatment for each patient challenging. Additionally, many patients continue to receive chemoimmunotherapy in the United States, suggesting a gap between guidelines and real-world practice. The Lymphoma Research Foundation convened a workshop comprising a panel of CLL/SLL experts in the United States to develop consensus recommendations for selection and sequencing of therapies for patients with CLL/SLL in the United States. Herein, the recommendations are compiled for use as a practical clinical guide for treating providers caring for patients with CLL/SLL, which complement existing guidelines by providing a nuanced discussion relating how our panel of CLL/SLL experts in the United States care for patients in a real-world environment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Soumerai JD, Barrientos J, Ahn I, et al. Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025. PMID: 39561376. doi:10.1182/bloodadvances.2024014474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。